Ontario Man Fighting Stage 4 Cancer Seeking Answers on Out-of-Country Coverage Denial
Ontario denied coverage for the treatment, which could cost about $1 million, while the province reviews whether to fund it publicly.
- On Thursday, July 9, 2026, Stage 4 cancer patient Alex Shved continues fighting for Ontario to fund his $1 million tumour-infiltrating lymphocyte therapy at Florida's Moffitt Cancer Center after the Ministry of Health denied his request this spring.
- The Ministry rejected the request, citing policy that prohibits out-of-country funding for medications currently undergoing national review processes; provinces participating in the Canadian Pharmaceutical Alliance do not provide interim funding.
- Joel Lexchin, professor emeritus at York University, noted it takes an average of 730 days for funding decisions following Health Canada approval, and public payers avoid American treatments because patented drug prices are up to three times higher than Canadian costs.
- Shved appealed to the Health Services Appeal and Review Board and contacted Health Minister Sylvia Jones, who called him recently but stated she cannot intervene in individual cases, though she offered to discuss the matter with her team.
- Lifileucel, a version of TIL therapy, received Health Canada approval last year and is currently undergoing provincial funding reviews, while Shved continues his fight for transparency to secure access before his condition progresses further.
24 Articles
24 Articles
Ontario cancer patient fights denial of out-of-country TIL therapy funding
Alex Shved is fighting his Stage 4 cancer on two fronts. Medication he is receiving as part of an early-stage trial is working with his body, he hopes, to attack melanoma that has metastasized. At the same time, he is taking up arms against another formidable foe: the health-care bureaucracy. Shved, 37, has tried various treatments since first discovering a growing mole in 2020 and continues to feel well, working in private equity and parenting …
Ontario man fighting Stage 4 cancer fights denial of out-of-country treatment coverage
Medication Alex Shved is receiving as part of an early-stage trial is working with his body, he hopes, to attack melanoma that has metastasized. At the same time, he is taking up arms against another formidable foe: the healthcare bureaucracy.
Ontario man fighting Stage 4 cancer seeking answers on out-of-country coverage denial – 105.9 The Region
TORONTO — Alex Shved is fighting his Stage 4 cancer on two fronts. Medication he is receiving as part of an early-stage trial is working with his body, he hopes, to attack melanoma that has metastasized. At the same time, he is taking up arms against another formidable foe: the health-care bureaucracy. Shved, 37, has tried various treatments since first discovering a growing mole in 2020 and continues to feel well, working in private equity and …
Coverage Details
Bias Distribution
- 78% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
